Q2 Half-yearly report

January–June 2026

President and CEO Hannu Martola | 6 August 2026

Q2 2026

25.6	5.1	1.8	7.1
net sales, €m (24.4)	net sales change-% (-6.6)	EBITA, €m (1.7)	EBITA-% (7.0)

Q2: Growth continued, driven by medical applications

TFT growth started also in Western markets, China weighed on security and industrial sales

Industrial sales -6%

- Sales of line scans declined
- TFT sales grew on all geographical markets

Medical sales +21%

- Growth driven by global CT demand
- Medical TFT deliveries commenced

Security sales -8%

- Growth in Western markets and APAC outside China
  - China impacted by weak line scan and CT demand
- Position and market share unchanged

Net sales by quarter



5.1

(YOY change-%)

Operating margin (EBITA) excluding NRI



Q2 2026 sales split by regional business units



	NET SALES €m	YOY CHANGE-%
AMERICAS	1.7	14.8
APAC	18.5	1.8
EMEIA	5.4	14.8

Q2 2026 sales split by main applications



	NET SALES €m	YOY CHANGE-%
INDUSTRIAL	5.2	-6.4
MEDICAL	12.8	21.3
SECURITY	7.6	-7.9

H1 2026

50.9	9.1	4.2	8.2
net sales, €m (46.6)	net sales change-% (-4.5)	EBITA, €m (3.1)	EBITA-% (6.7)

H1 2026 sales split by regional business units



	NET SALES €m	YOY CHANGE-%
AMERICAS	2.9	21.4
APAC	36.1	5.6
EMEIA	11.9	18.0

H1 2026 sales split by main applications



	NET SALES €m	YOY CHANGE-%
INDUSTRIAL	9.8	5.6
MEDICAL	25.4	18.5
SECURITY	15.7	-1.5

Key figures

	Q2 2026	Q2 2025	H1 2026	H1 2025	FY 2025
Net sales, EUR 1,000	25,606	24,372	50,870	46,621	101,023
Change in net sales, %	5.1%	-6.6%	9.1%	-4.5%	-6.0%
EBITA, EUR 1,000	1,830	1,702	4,181	3,101	9,255
EBITA, %	7.1%	7.0%	8.2%	6.7%	9.2%
R&D costs, EUR 1,000	2,823	3,146	5,595	5,781	11,266
R&D costs, % of net sales	11.0%	12.9%	11.0%	12.4%	11.2%
Cash flow from operating activities, EUR 1,000	-610	458	-4,028	1,897	3,885
Investments, EUR 1,000	3,280	1,144	3,689	1,548	2,965
Return on net assets (RONA, 12-month rolling), %	19.9%	26.8%	19.9%	26.8%	20.4%
Earnings per share, EUR	0.11	0.07	0.24	0.11	0.44

DT 2030

Strategic levers

BASE

Continue to do what we do, **better**

TFT

Drive **TFT flat panel growth**, across regions and markets

ADDED VALUE

Commercialize more value-added **integrated HW-SW** solutions to a broader customer base

NEW TECH

Seek new opportunities beyond current scope (Photon counting & SW)

Being the most trusted partner that drives **customer success through exceptional usability**

Elevate **performance culture**

Progress made to achieve 65 €M additional sales by 2030

Actions

- Launched 60+ TFT products
- Launched X-Panel 43108 and 4386
- Introduced IGZO-TFT products for EV battery and dental applications

- Launched AIDA, more added-value HW-SW detector system
- Launched X-ACE high-speed medical CT family

- Launched AVA low-cost family
- Developing both low-cost and high-performance CT products

- Launched X-Cargo

- Developing new photon-counting technology

- Opened sales and production site in India, granted Medical Device Mfg License
- Started a new site in Shanghai
- Expanded EU Origin production in Oulu

By application	€M
TFT: Medical and industrial	20
Medical, industrial: CT and line scan	20
Security: CT and line scan	15
Security cargo	10
TOTAL	**65**

By region	€M
APAC	33
EMEIA	20
Americas	12
TOTAL	**65**



Maintained strong momentum in TFT sales

Sales grew by 20% in H1 (YoY)

Growth for industrial applications in all regions

Medical TFT deliveries started

Order backlog grows in all regions

DT now has the world’s best set of fast and large single-glass flat panel detectors

Responded to defense industry demand with its proven XL series

- Stepping into the era of quantity: Defence drives demand for fast and large-scale scanning for high throughput and quality
- Launched X-Panel 4386 after 43108
- Fraunhofer IIS in Germany has verified the large panels for use in the weapons industry
- Positions DT as no. 1 in high-value industrial and defence inspection markets

“A real game-changer of industrial CT”

Michael Salamon
Group Manager, High-Energy X-ray Systems, Fraunhofer IIS

TFT

Transition to IFRS reporting

- Started preparations to transition from Finnish Accounting Standards (FAS) to International Financial Reporting Standards (IFRS)
- Expects to **improve the comparability of its financial reporting** with international peer companies, **support the execution of the DT2030 strategy**, and **enhance its attractiveness** to international investors
- Publishes its financial statements review for the financial year ending 31 December 2026 in accordance with IFRS
- The IFRS transition date will be 1 January 2025
- The IFRS transition release, including comparative information, is expected to be published towards the end of 2026

Sales expectation Q3 and Q4 2026

Industrial
to grow
in Q3

Medical
to grow
in Q3

Security
to decline
in Q3

Q3 sales are expected to grow in APAC and the Americas, and to decline in EMEIA

YOY total net sales to **grow in Q3** and **Q4 2026**

Business outlook

Detection Technology expects **total net sales to grow year-on-year in Q3 and Q4 2026**.

The geopolitical situation, new U.S. import tariffs, material constraints, and price competition create uncertainty.





FINANCIAL TARGETS

MEDIUM TERM Annual sales growth	MEDIUM TERM Operating margin (EBITA)	ANNUAL Dividend
>10%	15%	30-60%

Detection Technology

www.deetee.com